Head Lice News and Research

RSS

Head lice infestation is also called “Pediculosis capitis”. “Pediculosis” refers to louse infestation and “capitis” means the head.

Tackling Zika: are insect repellents the answer? An interview with Bruno Jactel

The repellents that are used today are mostly based on what we call chemical pesticides. These products are used to repel mosquitoes as well as ticks. They are very broadly used, but there are different issues surrounding their use.

19 May 2016

TyraTech launches award-winning head lice products, enters into French market

TyraTech, Inc., a life sciences technology company focused on nature-derived insect and parasite control products, announces a number of new initiatives including its expansion into the European market; the launch of a new product to complement the Vamousse range: Vamousse Lice Elimination for home cleaning; and further expansion of its distribution network in both the US and the UK.

12 Apr 2016

Hedrin celebrates 10th anniversary with launch of new packaging

Hedrin, the UK’s number 1 head lice brand, is celebrating its 10th birthday with a complete refresh of the packaging, to be available in pharmacies from April.

17 Mar 2016

Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare Corp. ("Concordia" or the "Company"), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30, 2014.

14 Nov 2014

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy.

7 Oct 2014

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada.

2 Sep 2014

FDA grants PMA for Pinnacle's Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber

Concordia Healthcare Corp. announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration premarket supplemental approval (PMA) for its Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber.

26 Mar 2014

Concordia Healthcare enters into definitive agreement to acquire Donnatal

Concordia Healthcare Corp., announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS") and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals").

20 Mar 2014

Concordia Healthcare acquires Pinnacle Biologics

Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs, announced today that it has acquired Pinnacle Biologics, Inc., a U.S.-based biopharmaceutical company specializing in legacy pharmaceuticals which have the potential for development as orphan drugs to treat cancer indications in addition to those for which they have previously been approved.

24 Dec 2013

Tips for parents to help their kids get a smart start to the academic year

The first day of school always requires preparations -- notebooks, pens and a new set of clothes. But don't forget to prepare for your child's health, says Dr. Joan Bregstein, a physician in the Division of Pediatric Emergency Medicine at NewYork-Presbyterian/Morgan Stanley Children's Hospital.

30 Aug 2012

Guidelines for parents to beat back-to-school bugs

School bells are beginning to sound again across the country, so it will only be a matter of time until every parent comes face-to-face with a child who wakes up with a cold, fever or upset stomach.

24 Aug 2012

Tips to prevent illness in crowds

Massive crowds from around the globe will mingle in London during the Olympics, and that means a world-class array of germs will mix with them. Mayo Clinic infectious diseases expert Gregory Poland, M.D., offers several tips for avoiding illness when you are around lots of people, whether at the Olympics, a professional football game, convention, arena concert or other major event.

26 Jul 2012

Pernix to acquire Great Southern

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced that it has entered into a definitive agreement to acquire Great Southern Laboratories, a privately-held pharmaceutical contract manufacturing company located in Houston, Texas.

3 Jul 2012

Pernix Therapeutics introduces Omeclamox-Pak® for the treatment of H. pylori infection and duodenal ulcer disease

Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.

21 May 2012

Study: Body and head lice are the same species

A new study offers compelling genetic evidence that head and body lice are the same species. The finding is of special interest because body lice can transmit deadly bacterial diseases, while head lice do not.

10 Apr 2012

Pernix fourth quarter net revenues increase 74% to $21.4 million

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced financial results for the quarter and year ended December 31, 2011.

29 Mar 2012

FDA approves ivermectin lotion for treatment of head lice

Sanofi announced today that the U.S. Food and Drug Administration (FDA) has approved Sklice® (ivermectin) lotion, 0.5% for the topical treatment of head lice, in patients 6 months of age and older. Effective and well-tolerated, Sklice Lotion treats lice in most patients with a single 10-minute application of the lotion, without nit combing.

7 Feb 2012

Pernix obtains marketing rights to new gastroenterology product in the U.S.

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced it has entered into a license and supply agreement with a private company for a new FDA-approved prescription product to treat gastroenterology disease.

24 Jan 2012

Positive results from Hatchtech's DeOvo Phase 2b trial on head lice

Specialty pharmaceutical company Hatchtech Pty Ltd today announced positive results for its Phase 2b clinical trial in subjects with head lice infestation. The results confirmed that DeOvo, a topical head lice treatment, is both safe and highly effective following a single application.

15 Dec 2011

Natroba effective against head lice and nits

ParaPRO, LLC, announced that researchers have presented data showing the effectiveness of Natroba (spinosad) Topical Suspension, 0.9% against head lice and nits following one treatment without nit combing. Those data about the pediculicide, derived from a naturally-occurring soil bacterium, were presented in a poster session on Saturday, Oct. 15, 2011 at the American Academy of Pediatrics National Conference and Exhibition in Boston.

18 Oct 2011